title: RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration.
abstract: As the most common malignant brain tumors, glioblastoma multiforme (GBM) was characterized by angiogenesis and tumor cells proliferation. Dual targeting to neovasculature and GBM cells could deliver cargoes to these two kinds of cells, leading to a combination treatment. In this study, polymeric nanoparticles were functionalized with RGD and interleukin-13 peptide (IRNPs) to construct a neovasculature and tumor cell dual targeting delivery system in which RGD could target αvβ3 on neovasculature and interleukin-13 peptide could target IL13Rα2 on GBM cells. In vitro, interleukin-13 peptide and RGD could enhance the uptake by corresponding cells (C6 and human umbilical vein endothelial cells). Due to the expression of both receptors on C6 cells, RGD also could enhance the uptake by C6 cells. Through receptor labeling, it clearly showed that αvβ3 could mediate the internalization of RGD modified nanoparticles and IL13Rα2 could mediate the internalization of interleukin-13 peptide modified nanoparticles. The ligand functionalization also resulted in a modification on endocytosis pathways, which changed the main endocytosis pathways from macropinocytosis for unmodified nanoparticles to clathrin-mediated endocytosis for IRNPs. IRNPs also displayed the strongest penetration ability according to tumor spheroid analysis. In vivo, IRNPs could effectively deliver cargoes to GBM with higher intensity than monomodified nanoparticles. After CD31-staining, it demonstrated IRNPs could target both neovasculature and GBM cells. In conclusion, IRNPs showed promising ability in dual targeting both neovasculature and GBM cells.
authors: Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, Department of Pharmaceutics Sciences, School of Pharmacy, Fudan University , 826 Zhangheng Road, Shanghai 201203, China.
authors: Huile
authors: H
authors: Gao
authors: Yang
authors: Y
authors: Xiong
authors: Shuang
authors: S
authors: Zhang
authors: Zhi
authors: Z
authors: Yang
authors: Shijie
authors: S
authors: Cao
authors: Xinguo
authors: X
authors: Jiang
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects; D015153:Blotting, Western; D001932:Brain Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D002463:Cell Membrane Permeability / Q000187:drug effects; D049109:Cell Proliferation; D002478:Cells, Cultured; D016503:Drug Delivery Systems; D004705:Endocytosis; D005434:Flow Cytometry; D005909:Glioblastoma / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors; D018793:Interleukin-13 / Q000008:administration & dosage* / Q000494:pharmacology; D053663:Interleukin-13 Receptor alpha2 Subunit / Q000037:antagonists & inhibitors; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D009842:Oligopeptides / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D039302:Integrin alphaVbeta3; D018793:Interleukin-13; D053663:Interleukin-13 Receptor alpha2 Subunit; D009842:Oligopeptides; C047981:arginyl-glycyl-aspartic acid
keywords: RGD; dual targeting delivery; glioma; interleukin-13 peptide; neovasculature